The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)

This study is currently recruiting participants.
Verified May 2012 by Rabin Medical Center
Sponsor:
Information provided by (Responsible Party):
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00768820
First received: October 7, 2008
Last updated: May 31, 2012
Last verified: May 2012

October 7, 2008
May 31, 2012
May 2001
December 2012   (final data collection date for primary outcome measure)
Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00768820 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Not Provided
Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Velocardiofacial Syndrome
  • Williams Syndrome
  • Fragile X Syndrome
Drug: methylphenidate, fluoxetin, risperidone
first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
Experimental: 1
Intervention: Drug: methylphenidate, fluoxetin, risperidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • chromosomal deletion proven by FISH examination

Exclusion Criteria:

Both
Not Provided
No
Contact: Doron Gothelf, MD 972-03-9253186 gothelf@post.tau.ac.il
Israel
 
NCT00768820
SCMCI082455CTIL
Yes
Rabin Medical Center
Rabin Medical Center
Not Provided
Not Provided
Rabin Medical Center
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP